A UNC Chapel Hill study of more than 2,300 middle schoolers found AI chatbot use jumped from 62% to 75% in four months, and students who used chatbots for emotional companionship went on to report greater loneliness and higher social anxiety.
Dartmouth's Therabot chatbot cut depression symptoms 51% in a 210-person randomized trial, and its creators are now racing to commercialize it even though the FDA has yet to clear any AI device specifically for mental health.
The FDA granted Breakthrough Device Designation in March 2026 to PathAI's PathAssist Derm, an AI tool meant to help pathologists on ambiguous skin biopsies — a category where studies show diagnostic concordance between pathologists falls below 50%.
A deep learning model called AgeNet, trained on over 420,000 chest X-rays from Korean adults and tracked for a median of 8.5 years, found that patients whose AI-estimated 'radiographic age' outpaced their real age had up to 52% higher mortality risk, per a study published in Radiology: Artificial Intelligence.
Insilico Medicine used its generative AI platform Chemistry42 to design ISM1354, a GIPR-blocking obesity drug candidate meant to pair with GLP-1 therapies and preserve muscle mass — showing 75-104% oral bioavailability and an 18-fold plasma exposure edge over a benchmark compound in animal studies.
Vanderbilt University Medical Center is running the VTE-AI randomized trial, one of the first studies testing whether an AI-driven electronic health record alert — built from 132,330 patient encounters — can cut hospital-acquired blood clots across both urban and rural hospitals.
Vanderbilt University Medical Center is running the VTE-AI randomized trial, one of the first studies testing whether an AI-driven electronic health record alert — built from 132,330 patient encounters — can cut hospital-acquired blood clots across both urban and rural hospitals.
Twelve U.S. health systems treating nearly 20 million patients a year have formed a consortium with Aidoc to rigorously test diagnostic imaging AI — a response to research showing only 3 of 1,357 FDA-cleared AI devices have been tested for actual patient benefit.
Italy's Garante fined Luka Inc., maker of the AI companion app Replika, €5 million for GDPR violations including inadequate age verification — three years after first suspending the app over child-safety concerns.
California's first-in-the-nation ban on AI-only health insurance denials is now the model for insurance AI bills in dozens of states, even as insurers warn a 50-state patchwork of rules is emerging in its wake.